Terri Vidals
Terri Vidals
Revolutionizing Healthcare: Wolters Kluwer's Acquisition of Invistics Flowlytics Diversion Software
Revolutionizing Healthcare: Wolters Kluwer's Acquisition of Invistics Flowlytics Diversion Software
Revolutionizing Healthcare: Wolters Kluwer's Acquisition of Invistics Flowlytics Diversion Software
Wednesday 7th August 2024
Terri Vidals chats with Karen Kobelski about Wolters Kluwer's acquisition of Invistics Flowlytics and its impact on drug diversion detection.
31 minutes
Informative
Innovative
Supportive
Educational
Engaging
About this podcast
Author:
Terri Vidals
Overview:
Categories:
Innovative Treatments & Recovery Paths
Nutritional Pathways to Recovery
Family Recovery from Addiction
Navigating Intimate Relationships
Recovery Reimagined
Links:
Visit site
Episodes:
121 (View all)
Do you want to link to this podcast?
Get the buttons here!Revolutionising Healthcare: Wolters Kluwer's Game-Changing Move
Episode Overview
- Wolters Kluwer has acquired Invistics Flowlytics to enhance drug diversion detection.
- Karen Kobelski shares her transition from financial services to healthcare.
- The new software uses AI and machine learning for better detection.
- Challenges include integrating technology in smaller healthcare settings.
- Wolters Kluwer offers unique strengths like a common data integration platform.
Our solutions actually do end up saving lives and making a difference in the way patients are treated
In this episode of Drug Diversion Insights, host Terri Vidals sits down with Karen Kobelski, Vice President and General Manager at Wolters Kluwer, to discuss the groundbreaking acquisition of Invistics Flowlytics diversion software. Karen shares her journey from the financial services industry to healthcare, where she has spent the last 12 years integrating advanced technology with clinical workflows.
Wolters Kluwer, known for its deep-rooted history in medical publishing and clinical decision support, has now ventured into drug diversion detection with their new software, Century 7 Drug Diversion. This episode explores the rationale behind this strategic move and how it aims to safeguard healthcare environments from drug diversion. Karen explains that drug diversion technology had been lagging due to patent restrictions but has now evolved to harness AI and machine learning for better detection.
The conversation also touches on the importance of adapting user interfaces for different healthcare roles and the ongoing need to update AI models to stay ahead of new diversion tactics. You'll learn about the challenges of integrating technology in smaller healthcare settings and the unique strengths that Wolters Kluwer brings to the table, such as their common data integration platform and opioid stewardship solutions.
By the end of the episode, you'll have a comprehensive understanding of how Wolters Kluwer is revolutionising healthcare with their innovative approach to drug diversion detection. Tune in to discover how these advancements are making a real difference in patient care and safety.